Repare Free Cash Flow Yield vs Price To Sales Ratio Analysis

RPTX Stock  USD 3.28  0.04  1.20%   
Repare Therapeutics financial indicator trend analysis is much more than just breaking down Repare Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Repare Therapeutics is a good investment. Please check the relationship between Repare Therapeutics Free Cash Flow Yield and its Price To Sales Ratio accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repare Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.

Free Cash Flow Yield vs Price To Sales Ratio

Free Cash Flow Yield vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Repare Therapeutics Free Cash Flow Yield account and Price To Sales Ratio. At this time, the significance of the direction appears to have strong relationship.
The correlation between Repare Therapeutics' Free Cash Flow Yield and Price To Sales Ratio is 0.72. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Repare Therapeutics, assuming nothing else is changed. The correlation between historical values of Repare Therapeutics' Free Cash Flow Yield and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Repare Therapeutics are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Free Cash Flow Yield i.e., Repare Therapeutics' Free Cash Flow Yield and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.72
Relationship DirectionPositive 
Relationship StrengthSignificant

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Repare Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Repare Therapeutics sales, a figure that is much harder to manipulate than other Repare Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.
Most indicators from Repare Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Repare Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repare Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.Tax Provision is likely to drop to about 2.8 M in 2024. Selling General Administrative is likely to drop to about 18.4 M in 2024
 2021 2022 2023 2024 (projected)
Reconciled Depreciation1.5M2.0M1.9M1.2M
Total Operating Expenses116.3M151.6M167.4M84.1M

Repare Therapeutics fundamental ratios Correlations

0.920.830.780.850.510.860.88-0.78-0.840.560.80.860.620.530.910.70.870.070.870.880.730.680.850.90.92
0.920.840.80.980.680.950.98-0.91-0.820.470.930.950.50.681.00.610.93-0.130.860.990.660.490.980.911.0
0.830.840.910.870.280.910.86-0.61-0.930.320.640.850.660.460.830.690.92-0.430.940.840.840.240.870.940.84
0.780.80.910.80.160.80.79-0.52-0.820.00.550.730.460.310.80.520.82-0.40.850.770.740.340.80.780.81
0.850.980.870.80.670.980.96-0.88-0.820.420.90.940.490.660.980.610.94-0.30.840.990.660.311.00.920.98
0.510.680.280.160.670.610.67-0.91-0.230.60.870.690.010.820.680.140.460.260.280.710.010.370.670.510.68
0.860.950.910.80.980.610.93-0.83-0.860.470.840.920.570.610.950.670.95-0.330.870.970.720.260.980.960.95
0.880.980.860.790.960.670.93-0.91-0.820.50.930.990.490.780.970.570.92-0.150.870.970.640.460.960.920.97
-0.78-0.91-0.61-0.52-0.88-0.91-0.83-0.910.56-0.6-0.99-0.91-0.25-0.87-0.91-0.37-0.74-0.12-0.62-0.91-0.34-0.51-0.88-0.77-0.91
-0.84-0.82-0.93-0.82-0.82-0.23-0.86-0.820.56-0.45-0.63-0.81-0.86-0.36-0.81-0.89-0.960.41-0.99-0.81-0.96-0.27-0.82-0.93-0.81
0.560.470.320.00.420.60.470.5-0.6-0.450.620.580.560.580.450.580.480.320.440.490.370.390.420.60.46
0.80.930.640.550.90.870.840.93-0.99-0.630.620.930.360.840.930.470.80.060.690.930.440.510.90.80.93
0.860.950.850.730.940.690.920.99-0.91-0.810.580.930.510.820.950.590.91-0.130.870.950.640.440.940.940.95
0.620.50.660.460.490.010.570.49-0.25-0.860.560.360.510.070.480.980.75-0.350.790.510.930.110.490.70.5
0.530.680.460.310.660.820.610.78-0.87-0.360.580.840.820.070.680.120.520.170.460.680.120.390.660.620.67
0.911.00.830.80.980.680.950.97-0.91-0.810.450.930.950.480.680.60.92-0.130.850.990.650.50.980.91.0
0.70.610.690.520.610.140.670.57-0.37-0.890.580.470.590.980.120.60.82-0.340.820.630.940.160.610.760.61
0.870.930.920.820.940.460.950.92-0.74-0.960.480.80.910.750.520.920.82-0.380.960.940.870.280.940.960.93
0.07-0.13-0.43-0.4-0.30.26-0.33-0.15-0.120.410.320.06-0.13-0.350.17-0.13-0.34-0.38-0.35-0.21-0.480.71-0.3-0.26-0.13
0.870.860.940.850.840.280.870.87-0.62-0.990.440.690.870.790.460.850.820.96-0.350.840.920.340.840.930.85
0.880.990.840.770.990.710.970.97-0.91-0.810.490.930.950.510.680.990.630.94-0.210.840.650.380.990.920.99
0.730.660.840.740.660.010.720.64-0.34-0.960.370.440.640.930.120.650.940.87-0.480.920.650.160.660.80.66
0.680.490.240.340.310.370.260.46-0.51-0.270.390.510.440.110.390.50.160.280.710.340.380.160.310.340.49
0.850.980.870.81.00.670.980.96-0.88-0.820.420.90.940.490.660.980.610.94-0.30.840.990.660.310.920.98
0.90.910.940.780.920.510.960.92-0.77-0.930.60.80.940.70.620.90.760.96-0.260.930.920.80.340.920.91
0.921.00.840.810.980.680.950.97-0.91-0.810.460.930.950.50.671.00.610.93-0.130.850.990.660.490.980.91
Click cells to compare fundamentals

Repare Therapeutics Account Relationship Matchups

Repare Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding36.7M36.9M37.8M41.9M42.1M35.7M
Total Assets102.7M357.1M368.7M364.1M253.9M267.7M
Other Current Liab4K5.3M16.9M19.5M21.7M11.7M
Total Current Liabilities4.2M11.0M35.1M78.6M39.1M31.2M
Total Stockholder Equity(46.1M)286.8M288.4M279.5M212.1M183.0M
Other Liab8.1M55.9M39.6M2.7M3.1M2.9M
Net Tangible Assets(46.1M)286.8M288.4M279.5M321.4M173.0M
Property Plant And Equipment Net3.4M8.6M13.1M9.6M7.5M8.1M
Net Debt(93.7M)(322.2M)(327.1M)(154.1M)(107.9M)(113.3M)
Retained Earnings(49.9M)(103.4M)(210.3M)(239.3M)(333.1M)(316.5M)
Accounts Payable2.1M2.3M2.3M461K2.4M2.0M
Cash94.8M326.2M334.4M159.5M111.3M190.1M
Non Current Assets Total4.1M10.5M17.3M10.1M10.2M9.9M
Non Currrent Assets Other567K500K586K497K2.7M2.8M
Other Assets699K1.9M4.2M497K571.6K543.0K
Cash And Short Term Investments94.8M333.7M341.9M343.9M223.6M247.3M
Net Receivables3.1M6.2M3.2M4.3M15.3M16.1M
Liabilities And Stockholders Equity102.7M357.1M368.7M364.1M253.9M267.7M
Non Current Liabilities Total144.6M59.2M45.2M5.9M2.7M2.6M
Capital Lease Obligations1.1M4.0M7.3M5.4M3.4M3.9M
Other Current Assets719K6.7M6.3M5.7M4.7M4.5M
Other Stockholder Equity3.8M5.9M18.0M37.2M61.8M64.9M
Total Liab148.8M70.3M80.3M84.6M41.8M61.6M
Net Invested Capital(46.1M)286.8M288.4M279.5M212.1M183.0M
Property Plant And Equipment Gross3.4M8.6M13.1M9.6M14.8M9.4M
Total Current Assets98.6M346.6M351.4M354.0M243.7M257.8M
Net Working Capital94.3M335.5M316.3M275.4M204.6M226.7M
Property Plant Equipment3.4M8.6M5.6M9.6M11.0M6.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.